The long-term clinical course of acute deep venous thrombosis

Author(s): Prandoni P, Lensing AW, CogoA, Cuppini S, Villalta S, et al.


Background: In patients who have symptomatic deep venous thrombosis, the long-term risk for recurrent venous thromboembolism and the incidence and severity of post-thrombotic sequelae have not been well documented.

Objective: To determine the clinical course of patients during the 8 years after their first episode of symptomatic deep venous thrombosis.

Design: Prospective cohort study.

Setting: University outpatient thrombosis clinic.

Patients: 355 consecutive patients with a first episode of symptomatic deep venous thrombosis.

Measurements: Recurrent venous thromboembolism, the post-thrombotic syndrome, and death. Potential risk factors for these outcomes were also evaluated.

Results: The cumulative incidence of recurrent venous thromboembolism was 17.5% after 2 years of follow-up (95% CI, 13.6% to 22.2%), 24.6% after 5 years (CI, 19.6% to 29.7%), and 30.3% after 8 years (CI, 23.6% to 37.0%). The presence of cancer and of impaired coagulation inhibition increased the risk for recurrent venous thromboembolism (hazard ratios, 1.72 [CI, 1.31 to 2.25] and 1.44 [CI, 1.02 to 2.01], respectively). In contrast, surgery and recent trauma or fracture were associated with a decreased risk for recurrent venous thromboembolism (hazard ratios, 0.36 [CI, 0.21 to 0.62] and 0.51 [CI, 0.32 to 0.87], respectively). The cumulative incidence of the post-thrombotic syndrome was 22.8% after 2 years (CI, 18.0% to 27.5%), 28.0% after 5 years (CI, 22.7% to 33.3%), and 29.1% after 8 years (CI, 23.4% to 34.7%). The development of ipsilateral recurrent deep venous thrombosis was strongly associated with the risk for the post-thrombotic syndrome (hazard ratio, 6.4; CI, 3.1 to 13.3). Survival after 8 years was 70.2% (CI, 64.7% to 75.6%). The presence of cancer increased the risk for death (hazard ratio, 8.1; CI, 3.6 to 18.1).

Conclusion: Patients with symptomatic deep venous thrombosis, especially those without transient risk factors for deep venous thrombosis, have a high risk for recurrent venous thromboembolism that persists for many years. The post-thrombotic syndrome occurs in almost one third of these patients and is strongly related to ipsilateral recurrent deep venous thrombosis. These findings challenge the widely adopted use of short-course anticoagulation therapy in patients with symptomatic deep venous thrombosis.

Similar Articles

A prospective study of the incidence of deep-vein thrombosis within a defined urban population

Author(s): Nordström M, Lindblad B, Bergqvist D, Kjellström T

A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism

Author(s): Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, et al.

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

Author(s): Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, et al.

Age, an independent risk factor for thrombosis

Author(s): MahéI, Caulin C, Bergmann JF

Immobilization and the risk of venous thromboembolism

Author(s): Pottier P, Hardouin JB, Lejeune S, Jolliet P, Gillet B, et al.

Management of pulmonary embolism in a cardiology department

Author(s): OuldzeinH, Nourredine A, Cherradi R, Rahal N, Mechmeche R, et al.

Prolonged work- and computer-related seated immobility and risk of venous thromboembolism

Author(s): Healy B, Levin E, Perrin K, Weatherall M, Beasley R

Venous thromboembolism in Jamaican women: experience in a university hospital in Kingston

Author(s): Fletcher HM, Wharfe G, Williams NP, Pedican M, Brooks A, et al.

A prospective study of risk factors for pulmonary embolism in women

Author(s): Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, et al.

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Author(s): Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, et al.

Epidemiology of acute deep vein thrombosis

Author(s): BulgerCM, Jacobs C, Patel NH

Hormonal contraception and risk of venous thromboembolism: national follow-up study

Author(s): Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C

Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study

Author(s): Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, et al.

Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study

Author(s): Middeldorp S, Meijers JC, van den Ende AE, van Enk A, Bouma BN, et al.

Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives

Author(s): Alhenc-Gelas M, Plu-Bureau G, Guillonneau S, Kirzin JM, Aiach M, et al.

Effect of four different oral contraceptives on various sex hormones and serum-binding globulins

Author(s): Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, et al.

[Upper limb deep venous thrombosis]

Author(s): Benhamou Y, Marie I, David N, Gbaguidi X, Cailleux N, et al.

Old and new risk factors for upper extremity deep venous thrombosis

Author(s): Blom JW, Doggen CJ, Osanto S, Rosendaal FR

Homocysteine and vascular disease

Author(s): Hankey GJ, Eikelboom JW

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism

Author(s): Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, et al.